Bioventus (NASDAQ:BVS – Free Report) had its target price decreased by Canaccord Genuity Group from $19.00 to $18.00 in a report released on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.
Other research analysts have also issued reports about the company. Craig Hallum reissued a “buy” rating and set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Weiss Ratings upgraded Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Barrington Research set a $18.00 target price on Bioventus in a research note on Thursday, August 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, August 17th. Six investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $16.60.
View Our Latest Stock Report on BVS
Bioventus Trading Down 6.5%
NASDAQ BVS opened at $10.68 on Tuesday. Bioventus has a twelve month low of $6.47 and a twelve month high of $15.89. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.17 and a current ratio of 1.68. The stock has a market cap of $898.08 million, a price-to-earnings ratio of 13.35, a PEG ratio of 1.46 and a beta of 0.66. The firm’s 50 day moving average price is $13.50 and its two-hundred day moving average price is $10.95.
Bioventus (NASDAQ:BVS – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. The company had revenue of $142.44 million for the quarter. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. Equities analysts anticipate that Bioventus will post 0.78 EPS for the current year.
Hedge Funds Weigh In On Bioventus
Hedge funds have recently added to or reduced their stakes in the company. Covestor Ltd boosted its holdings in Bioventus by 25.6% in the third quarter. Covestor Ltd now owns 5,808 shares of the company’s stock worth $79,000 after purchasing an additional 1,182 shares in the last quarter. Quantum Financial Partners LLC raised its holdings in Bioventus by 11.8% during the third quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company’s stock valued at $194,000 after buying an additional 1,500 shares in the last quarter. Signaturefd LLC raised its holdings in Bioventus by 2,809.1% during the third quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock valued at $26,000 after buying an additional 1,854 shares in the last quarter. USA Financial Formulas acquired a new stake in shares of Bioventus in the third quarter worth about $42,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Bioventus by 4.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 85,874 shares of the company’s stock worth $1,170,000 after buying an additional 3,367 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.
About Bioventus
Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.
The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.
Featured Articles
- Five stocks we like better than Bioventus
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
